Shots:
- Merck has highlighted P-III (CORALreef HeFH) trial data assessing enlicitide decanoate (20mg, PO, QD) vs PBO in 303 adults with HeFH at AHA’25
- Trial showed significant LDL-C reductions (1EP), along with decreases in non-HDL-C (53%), ApoB (49.1%), & Lp(a) (27.5%) at Wk. 24 in HeFH pts on stable background lipid-lowering therapy. High adherence (97%) & dosing compliance (96%) in adults was also observed
- Enlicitide reduced LDL-C as early as Wk. 4 & by 61.5% at 1yr., plus 67.3% enlicitide-treated pts achieved ≥50% LDL-C reduction & <55 mg/dL vs 1% at 24wks.; data to be shared, along with CORALreef Lipids & CORALreef AddOn results with global health authorities & published in The JAMA
Ref: Merck | Image: Merck | Press Release
Related News:- Merck Receives EC’s Approval for Perioperative Keytruda for Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
